Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Study Details
Study Description
Brief Summary
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can kill chronic lymphocytic leukemia (CLL) cells and are effective therapies for this disease. Biological therapies, such as Imprime PGG (poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose), may stimulate the immune system in different ways and help monoclonal antibodies kill CLL cells. Giving PGG beta-glucan together with alemtuzumab and rituximab could make therapy with monoclonal antibodies, such as alemtuzumab and rituximab, more effective.
PURPOSE: This phase I/II trial is studying the side effects and best dose of PGG beta-glucan when given together with alemtuzumab and rituximab and to see how well it works in treating patients with earlier stage high-risk chronic lymphocytic leukemia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
PRIMARY OBJECTIVES:
- Determine the maximum tolerated dose of PGG beta glucan in combination with alemtuzumab and rituximab. (Phase I) II. Assess the rate of complete response of patients with high-risk, early-intermediate stage CLL who are treated with alemtuzumab, rituximab, and PGG beta glucan before meeting standard National Cancer Institute-International Workshop on Chronic Lymphocytic Leukemia (NCI-IWCLL) criteria (Hallek, Cheson et al. 2008) for treatment. (Phase
SECONDARY OBJECTIVES:
-
To monitor and assess toxicity of this regimen. II. Clinical evaluation of toxicity. III. Serial monitoring of cytomegalovirus (CMV) viral load by polymerase chain reaction (PCR).
-
To assess the rate of overall response in CLL patients using this treatment regimen.
-
To determine time to progression, time to next treatment, and duration of response in CLL patients using this treatment regimen.
TERTIARY OBJECTIVES:
-
To assess the correlation between the individual prognostic markers (17p-, 11q-, unmutated VH gene, use of VH3-21, ZAP70+, CD38+) and clinical outcome.
-
To assess response to this combination regimen using an expanded definition of response, including bone marrow studies with immunohistochemical studies for residual CLL cells and sensitive flow cytometry for minimal residual disease in patients in complete clinical remission.
OUTLINE: This is phase I, dose-escalation study of PGG beta-glucan followed by a phase II study.
Patients receive PGG beta-glucan intravenously (IV) over 2-4 hours on days 1, 5, 10, 17, 24, and 31; alemtuzumab subcutaneously (SC) on days 3, 4, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; and rituximab IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up monthly for 3 months, every 3 months for 1 year, and then every 6 months for 5 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm I Patients receive PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31; alemtuzumab subcutaneously on days 3, 4, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; and rituximab IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
Biological: alemtuzumab
Given subcutaneously
Other Names:
Biological: rituximab
Given IV
Other Names:
Drug: PGG beta-glucan
Given IV
Other Names:
Other: flow cytometry
Correlative studies
Other: laboratory biomarker analysis
Correlative studies
Genetic: DNA analysis
Correlative studies
Genetic: fluorescence in situ hybridization
Correlative studies
Other Names:
Genetic: polymerase chain reaction
Correlative studies
Other Names:
Genetic: polymorphism analysis
Correlative studies
Genetic: mutation analysis
Correlative studies
|
Outcome Measures
Primary Outcome Measures
- Maximum Tolerated Dose (MTD) of PGG Beta Glucan in Combination With Alemtuzumab and Rituximab Assessed by Analyzing the Number of Dose-limiting Toxicity Events (Phase I) [First cycle of treatment (35 days)]
MTD is defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients (at least 2 of a maximum of 6 new patients). A total of 6 patients treated at the MTD will be sufficient to identify common toxicities at the MTD. Three patients will be treated at a given dose level combination for at least 5 weeks to assess toxicity. If dose-limiting toxicity (DLT) is not seen in any of the 3 patients, 3 new patients will be accrued and treated at the next higher dose level. If DLT is seen in 2 or 3 of 3 patients treated at a given dose level, then the next 3 patients will be treated at the next lower dose level, if only 3 patients were enrolled and treated at this lower dose level. We tabulate the number of patients reporting a DLT.
- Proportion of Complete Responses (Dose Level 2) [3 months after the completion of treatment, up to 5 years]
The number of patients that demonstrate a Complete Response (CR) during treatment on Dose Level 2 divided by the number of eligible patients starting Dose Level 2 treatment. A CR requires all of the following for a period of at least 2 months: Absence of lymphadenopathy by physical examination, no hepatomegaly or splenomegaly, absence of constitutional symptoms, neutrophils >1500/ul, Platelets >100,000/ul, Hemoglobin >11.0 gm/dl, Peripheral blood lymphocytes <4000/uL.
Secondary Outcome Measures
- Overall Response Rate (Dose Level 2) [3 months after the completion of treatment, up to 5 years]
Overall response rate was estimated by the total number of patients receiving Dose Level 2 reporting complete responses or partial responses (CR or PR) divided by the total number of evaluable patients that started Dose Level 2 treatment. A COMPLETE RESPONSE (CR) requires all of the following for a period of at least 2 months: Absence of lymphadenopathy by physical examination, no hepatomegaly or splenomegaly, absence of constitutional symptoms, neutrophils >1500/ul, Platelets >100,000/ul, Hemoglobin >11.0 gm/dl, Peripheral blood lymphocytes <4000/uL. A PARTIAL RESPONSE (PR) requires the patient exhibits at least two of the features: ≥ 50% decrease in peripheral blood lymphocyte count from baseline, ≥ 50% reduction in the sum of the products of the maximal perpendicular diameters of the largest measured node or nodal masses in the right and left cervical, axillary, and inguinal lymph node regions on physical examination.
- Time to Disease Progression [Up to 5 years]
Time to disease progression is defined as the time from registration to the earliest date of documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. The distribution of time to disease progression will be estimated using the method of Kaplan-Meier.
- Duration of Response for All Evaluable Patients Who Have Achieved an Objective Response [Up to 5 years]
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the earliest date progression is documented. The distribution of duration of response will be estimated using the method of Kaplan-Meier.
- Time to Subsequent Therapy [Up to 5 years]
Time to subsequent therapy is defined to be the time from the end of active treatment date to the date subsequent therapy is initiated. The distribution of time to subsequent therapy will be estimated using the method of Kaplan-Meier.
- Number of Participants With Grade 3+ Adverse Events [up to 5 years of treatment]
Adverse events were collected at the end of each cycle according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The number of grade 3+ events at least possibly related to treatment are recorded. For a complete set of all recorded adverse events, please see the Adverse Events section of this report.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of CLL (Hallek, Cheson et al. 2008) manifested by: Minimum threshold peripheral lymphocyte count of 5 x 10^9/L AND immunophenotypic demonstrations of a population of B lymphocytes (as defined by CD19+) which are monoclonal (light chain exclusion); CLL will be diagnosed if these cells have >= 3 of the following characteristics: CD5+, CD23+, dim surface light chain expression, dim surface CD20 expression AND fluorescence in situ hybridization (FISH) analysis is negative for IGH/CCND1 and/or immunostaining is negative for cyclin D1 expression
-
= 1 of the following poor prognosis factors: unmutated IGHV (< 2%) AND CD38 expression (>= 30% cells positive on flow cytometry); unmutated IGHV (< 2%) AND ZAP-70 expression (>= 20% cells positive on flow cytometry); use of VH3-21 gene segment irrespective of mutation status AND CD38 expression (>= 30% cells positive on flow cytometry); use of VH3-21 gene segment irrespective of mutation status AND ZAP-70 expression (>= 20% cells positive on flow cytometry); 11q22-; 17p13-
-
Rai classification Stage 0, I or II that does not meet standard NCI-IWCLL criteria for treatment of CLL (Hallek, Cheson et al. 2008)
-
Limited CLL disease burden with no lymph nodes > 5 cm in any diameter and splenomegaly < 6 cm below left costal margin in midclavicular line at rest
-
Creatinine =< 1.5 x upper normal limit (UNL)
-
Total bilirubin =< 3.0 x UNL; if total is elevated, a direct bilirubin should be performed and should be =< 1.5 x UNL
-
AST =< 3.0 x UNL
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0, 1, or 2
-
Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
-
Provide informed written consent
-
Willing to return to a Lymphoma Specialized Program of Research Excellence (SPORE) enrolling institution for follow-up
-
Willing to provide blood samples for correlative research purposes
Exclusion Criteria:
-
Pregnant women
-
Nursing women
-
Men or women of childbearing potential who are unwilling to employ adequate contraception
-
New York Heart Association Class III or IV heart disease
-
Recent myocardial infarction (< 1 month)
-
Uncontrolled infection
-
Infection with the human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), serological evidence of active hepatitis B infection (HBsAg or HBeAg positive) or positive hepatitis C serology, as further severe immunosuppression with this regimen may occur
-
Evidence of active autoimmune hemolytic anemia, immune thrombocytopenia, or pure red blood cell aplasia
-
Other active primary malignancy requiring treatment or limits survival to =< 2 years
-
Any major surgery =< 4 weeks prior to registration
-
Any previous chemotherapy or monoclonal antibody treatment for CLL
-
Current use of corticosteroids; NOTE: previous corticosteroids are allowed
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
- National Cancer Institute (NCI)
Investigators
- Study Chair: Steven Ansell, M.D., Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LS1084
- NCI-2010-02329
- LS1084
- 10-003025
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Phase I: Dose Level 0 | Phase I: Dose Level 1 | Phase I: Dose Level 2 | Phase II: Dose Level 2 |
|---|---|---|---|---|
| Arm/Group Description | During one 35-day period of treatment: Patients receive 1 mg/kg/dose PGG (poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose) IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. | During one 35-day period of treatment: Patients receive 2 mg/kg/dose PGG (poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose) IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. | During one 35-day period of treatment: Patients receive 4 mg/kg/dose PGG (poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose) IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. | During one 35-day period of treatment: Patients receive 4 mg/kg/dose PGG (poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose) IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
| Period Title: Overall Study | ||||
| STARTED | 4 | 4 | 6 | 8 |
| COMPLETED | 3 | 3 | 6 | 8 |
| NOT COMPLETED | 1 | 1 | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | During one 35-day period of treatment: Patients receive 1, 2, or 4 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
| Overall Participants | 20 |
| Age (years) [Median (Full Range) ] | |
| Median (Full Range) [years] |
61
|
| Sex: Female, Male (Count of Participants) | |
| Female |
6
30%
|
| Male |
14
70%
|
| Region of Enrollment (participants) [Number] | |
| United States |
20
100%
|
Outcome Measures
| Title | Maximum Tolerated Dose (MTD) of PGG Beta Glucan in Combination With Alemtuzumab and Rituximab Assessed by Analyzing the Number of Dose-limiting Toxicity Events (Phase I) |
|---|---|
| Description | MTD is defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients (at least 2 of a maximum of 6 new patients). A total of 6 patients treated at the MTD will be sufficient to identify common toxicities at the MTD. Three patients will be treated at a given dose level combination for at least 5 weeks to assess toxicity. If dose-limiting toxicity (DLT) is not seen in any of the 3 patients, 3 new patients will be accrued and treated at the next higher dose level. If DLT is seen in 2 or 3 of 3 patients treated at a given dose level, then the next 3 patients will be treated at the next lower dose level, if only 3 patients were enrolled and treated at this lower dose level. We tabulate the number of patients reporting a DLT. |
| Time Frame | First cycle of treatment (35 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| All Phase I patients that were eligible and completed cycle 1 treatment were used in the MTD assessment. |
| Arm/Group Title | Phase I: Dose Level 0 | Phase I: Dose Level 1 | Phase I: Dose Level 2 |
|---|---|---|---|
| Arm/Group Description | During one 35-day period of treatment: Patients receive 1 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. | During one 35-day period of treatment: Patients receive 2 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. | During one 35-day period of treatment: Patients receive 4 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 3 | 3 | 6 |
| Count of Participants [Participants] |
0
0%
|
0
NaN
|
1
NaN
|
| Title | Proportion of Complete Responses (Dose Level 2) |
|---|---|
| Description | The number of patients that demonstrate a Complete Response (CR) during treatment on Dose Level 2 divided by the number of eligible patients starting Dose Level 2 treatment. A CR requires all of the following for a period of at least 2 months: Absence of lymphadenopathy by physical examination, no hepatomegaly or splenomegaly, absence of constitutional symptoms, neutrophils >1500/ul, Platelets >100,000/ul, Hemoglobin >11.0 gm/dl, Peripheral blood lymphocytes <4000/uL. |
| Time Frame | 3 months after the completion of treatment, up to 5 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| All patients treated at dose level 2 were included in this analysis. This includes 6 patients registered to the Phase I: Dose level 2 and 8 patients registered to Phase II. |
| Arm/Group Title | Dose Level 2 |
|---|---|
| Arm/Group Description | During one 35-day period of treatment: Patients receive 4 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 14 |
| Number (95% Confidence Interval) [proportion of participants] |
.65
3.3%
|
| Title | Overall Response Rate (Dose Level 2) |
|---|---|
| Description | Overall response rate was estimated by the total number of patients receiving Dose Level 2 reporting complete responses or partial responses (CR or PR) divided by the total number of evaluable patients that started Dose Level 2 treatment. A COMPLETE RESPONSE (CR) requires all of the following for a period of at least 2 months: Absence of lymphadenopathy by physical examination, no hepatomegaly or splenomegaly, absence of constitutional symptoms, neutrophils >1500/ul, Platelets >100,000/ul, Hemoglobin >11.0 gm/dl, Peripheral blood lymphocytes <4000/uL. A PARTIAL RESPONSE (PR) requires the patient exhibits at least two of the features: ≥ 50% decrease in peripheral blood lymphocyte count from baseline, ≥ 50% reduction in the sum of the products of the maximal perpendicular diameters of the largest measured node or nodal masses in the right and left cervical, axillary, and inguinal lymph node regions on physical examination. |
| Time Frame | 3 months after the completion of treatment, up to 5 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| All patients treated at dose level 2 were included in this analysis. This includes 6 patients registered to the Phase I: Dose level 2 and 8 patients registered to Phase II. |
| Arm/Group Title | Dose Level 2 |
|---|---|
| Arm/Group Description | During one 35-day period of treatment: Patients receive 4 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 14 |
| Number (95% Confidence Interval) [proportion of patients] |
.93
|
| Title | Time to Disease Progression |
|---|---|
| Description | Time to disease progression is defined as the time from registration to the earliest date of documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. The distribution of time to disease progression will be estimated using the method of Kaplan-Meier. |
| Time Frame | Up to 5 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| All 20 eligible patients that started and completed protocol treatment were combined in this analysis to assess overall benefit of protocol treatment. |
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | During one 35-day period of treatment: Patients receive 1, 2, or 4 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 20 |
| Median (95% Confidence Interval) [months] |
17.6
|
| Title | Duration of Response for All Evaluable Patients Who Have Achieved an Objective Response |
|---|---|
| Description | Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the earliest date progression is documented. The distribution of duration of response will be estimated using the method of Kaplan-Meier. |
| Time Frame | Up to 5 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| Data was not collected to run this analysis. |
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | During one 35-day period of treatment: Patients receive 1, 2, or 4 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 0 |
| Title | Time to Subsequent Therapy |
|---|---|
| Description | Time to subsequent therapy is defined to be the time from the end of active treatment date to the date subsequent therapy is initiated. The distribution of time to subsequent therapy will be estimated using the method of Kaplan-Meier. |
| Time Frame | Up to 5 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| All 20 eligible patients that started and completed protocol treatment were combined in this analysis to assess overall benefit of protocol treatment. |
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | During one 35-day period of treatment: Patients receive 1, 2, or 4 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 20 |
| Median (95% Confidence Interval) [months] |
NA
|
| Title | Number of Participants With Grade 3+ Adverse Events |
|---|---|
| Description | Adverse events were collected at the end of each cycle according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The number of grade 3+ events at least possibly related to treatment are recorded. For a complete set of all recorded adverse events, please see the Adverse Events section of this report. |
| Time Frame | up to 5 years of treatment |
Outcome Measure Data
| Analysis Population Description |
|---|
| All 20 eligible patients that started and completed protocol treatment were combined in this analysis to assess overall effect of protocol treatment. |
| Arm/Group Title | All Patients |
|---|---|
| Arm/Group Description | During one 35-day period of treatment: Patients receive 1, 2, or 4 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 20 |
| Grade 3 Adverse Event |
1
5%
|
| Grade 4 Adverse Event |
2
10%
|
Adverse Events
| Time Frame | ||||||
|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||
| Arm/Group Title | Dose Level 0 | Dose Level 1 | Dose Level 2 | |||
| Arm/Group Description | During one 35-day period of treatment: Patients receive 1 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3, 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. | During one 35-day period of treatment: Patients receive 2 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3, 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. | During one 35-day period of treatment: Patients receive 4 mg/kg/dose PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31 Alemtuzumab subcutaneously 3 mg day 3, 10 mg day 4 30 mg days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Rituximab 375 mg/m2 IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity. | |||
All Cause Mortality |
||||||
| Dose Level 0 | Dose Level 1 | Dose Level 2 | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/4 (0%) | 0/4 (0%) | 0/14 (0%) | |||
Serious Adverse Events |
||||||
| Dose Level 0 | Dose Level 1 | Dose Level 2 | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/4 (0%) | 1/4 (25%) | 4/14 (28.6%) | |||
| Blood and lymphatic system disorders | ||||||
| Febrile neutropenia | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Gastrointestinal disorders | ||||||
| Diarrhea | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 2/14 (14.3%) | 2 |
| Gastritis | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| General disorders | ||||||
| Fever | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Metabolism and nutrition disorders | ||||||
| Dehydration | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Skin and subcutaneous tissue disorders | ||||||
| Urticaria | 0/4 (0%) | 0 | 1/4 (25%) | 1 | 0/14 (0%) | 0 |
| Vascular disorders | ||||||
| Hypertension | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Hypotension | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
Other (Not Including Serious) Adverse Events |
||||||
| Dose Level 0 | Dose Level 1 | Dose Level 2 | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 4/4 (100%) | 4/4 (100%) | 14/14 (100%) | |||
| Blood and lymphatic system disorders | ||||||
| Anemia | 4/4 (100%) | 5 | 3/4 (75%) | 6 | 11/14 (78.6%) | 40 |
| Cardiac disorders | ||||||
| Mitral valve disease | 0/4 (0%) | 0 | 1/4 (25%) | 1 | 0/14 (0%) | 0 |
| Gastrointestinal disorders | ||||||
| Diarrhea | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Dyspepsia | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Nausea | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 2/14 (14.3%) | 2 |
| Vomiting | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| General disorders | ||||||
| Chills | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Fatigue | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 4/14 (28.6%) | 6 |
| Fever | 3/4 (75%) | 5 | 2/4 (50%) | 2 | 4/14 (28.6%) | 5 |
| Immune system disorders | ||||||
| Cytokine release syndrome | 2/4 (50%) | 2 | 1/4 (25%) | 1 | 0/14 (0%) | 0 |
| Infections and infestations | ||||||
| Bladder infection | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Bronchial infection | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Infections and infestations - Other, specify | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 4/14 (28.6%) | 5 |
| Lung infection | 1/4 (25%) | 1 | 1/4 (25%) | 1 | 1/14 (7.1%) | 2 |
| Peripheral nerve infection | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Pharyngitis | 1/4 (25%) | 1 | 0/4 (0%) | 0 | 0/14 (0%) | 0 |
| Sinusitis | 0/4 (0%) | 0 | 1/4 (25%) | 1 | 0/14 (0%) | 0 |
| Upper respiratory infection | 1/4 (25%) | 1 | 0/4 (0%) | 0 | 3/14 (21.4%) | 4 |
| Urinary tract infection | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Investigations | ||||||
| Alanine aminotransferase increased | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Aspartate aminotransferase increased | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Lymphocyte count decreased | 4/4 (100%) | 7 | 4/4 (100%) | 13 | 14/14 (100%) | 43 |
| Lymphocyte count increased | 1/4 (25%) | 1 | 0/4 (0%) | 0 | 0/14 (0%) | 0 |
| Neutrophil count decreased | 1/4 (25%) | 1 | 1/4 (25%) | 3 | 6/14 (42.9%) | 7 |
| Platelet count decreased | 3/4 (75%) | 5 | 3/4 (75%) | 9 | 7/14 (50%) | 23 |
| White blood cell decreased | 3/4 (75%) | 3 | 2/4 (50%) | 4 | 8/14 (57.1%) | 15 |
| Metabolism and nutrition disorders | ||||||
| Hyponatremia | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Hypophosphatemia | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Musculoskeletal and connective tissue disorders | ||||||
| Arthritis | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 2 |
| Nervous system disorders | ||||||
| Headache | 0/4 (0%) | 0 | 1/4 (25%) | 1 | 0/14 (0%) | 0 |
| Neuralgia | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||||||
| Allergic rhinitis | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Bronchospasm | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Skin and subcutaneous tissue disorders | ||||||
| Erythema multiforme | 1/4 (25%) | 1 | 0/4 (0%) | 0 | 0/14 (0%) | 0 |
| Pruritus | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
| Rash maculo-papular | 2/4 (50%) | 2 | 2/4 (50%) | 3 | 9/14 (64.3%) | 11 |
| Urticaria | 0/4 (0%) | 0 | 0/4 (0%) | 0 | 1/14 (7.1%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Stephen M. Ansell MD |
|---|---|
| Organization | Mayo Clinic |
| Phone | |
| Ansell.Stephen@mayo.edu |
- LS1084
- NCI-2010-02329
- LS1084
- 10-003025